Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Serelaxin versus placebo for vascular function in coronary artery disease
2012-001945-42Phase 2Completed
- Sponsor
- Novartis
- Start
- Aug 2013
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in coronary arteriosclerosis comparing Serelaxin with Placebo (2 arms). Primary endpoints: Change from baseline in microvascular function and Coronary vasculature effect at end of treatment. Started Aug 2013; status: completed.
02
Drugs
serelaxin
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on 2012-001945-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-001945-42.